Xolair

At Latitude, we offer Xolair (omalizumab) in conjunction with OIT for our patients who require additional protection. Xolair is an anti-IgE monoclonal antibody by Genentech and Novartis that works by inhibiting the allergic reaction process. It is FDA approved for use in asthma in children over age 6 and chronic urticaria in children over age 12. Xolair has been granted Breakthrough Therapy Designation for the prevention of severe allergic reactions to food allergy by the FDA. Our clinical team can determine whether you or your child may be a good candidate for Xolair.